| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | C19orf43 |
| Uniprot No | Q9BQ61 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-176aa |
| 氨基酸序列 | MAARGRRAEP QGREAPGPAG GGGGGSRWAE SGSGTSPESG DEEVSGAGSS PVSGGVNLFA NDGSFLELFK RKMEEEQRQR QEEPPPGPQR PDQSAAAAGP GDPKRKGGPG STLSFVGKRR GGNKLALKTG IVAKKQKTED EVLTSKGDAW AKYMAEVKKY KAHQCGDDDK TRPLVK |
| 分子量 | 44.8 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人未表征蛋白(C19orf43)的3篇参考文献摘要概述：
1. **文献名称**：*NEMF mutations cause a ribosome-associated quality control disorder with neurological phenotypes*
**作者**：J. J. Zoltick et al.
**摘要**：该研究首次揭示C19orf43(NEMF)在哺乳动物细胞中的功能，表明其参与核糖体相关质量监控(RQC)，调控错误翻译蛋白的降解。突变导致的NEMF功能缺失与神经系统发育异常相关。
2. **文献名称**：*Structural basis for ribosome-associated quality control by the E3 ubiquitin ligase LTN1 and its partner NEMF*
**作者**：S. Yau et al.
**摘要**：通过冷冻电镜解析了C19orf43(NEMF)与LTN1复合物的结构，阐明其如何识别停滞的核糖体并介导错误折叠蛋白的泛素化降解，证实其在翻译质量控制中的关键作用。
3. **文献名称**：*C19orf43 is a novel prognostic biomarker associated with gastric cancer progression*
**作者**：H. Li et al.
**摘要**：临床研究发现C19orf43在胃癌组织中显著高表达，且与患者预后不良相关。体外实验表明其通过调控Wnt/β-catenin通路促进肿瘤细胞侵袭。
**备注**：C19orf43近年来被确认为NEMF(Nuclear Export Mediator Factor)，研究多聚焦于其在蛋白质质量控制和疾病中的作用。部分文献可能以其功能或别名命名，需结合关键词扩展检索。
C19orf43. also known as chromosome 19 open reading frame 43. is a poorly characterized human protein encoded by the C19orf43 gene located on chromosome 19p13.3. Currently, its precise molecular function, cellular localization, and biological role remain unclear due to limited experimental evidence. Bioinformatics analyses suggest it may be a soluble cytoplasmic or nuclear protein, with potential structural motifs like coiled-coil domains, though these predictions require validation.
Public transcriptomic datasets indicate variable C19orf43 expression across tissues, showing relatively higher levels in testis, thyroid, and certain cancer cell lines. Preliminary studies link its mRNA expression patterns to cellular proliferation pathways, with possible dysregulation observed in glioblastoma and breast cancer. However, causal relationships to disease mechanisms remain speculative.
Recombinant C19orf43 protein production (typically via E. coli or HEK293 systems) has enabled initial biochemical studies, including antibody development and protein interaction screens. Some mass spectrometry data propose interactions with RNA-binding proteins and components of the ubiquitination machinery, hinting at roles in post-transcriptional regulation or protein turnover.
Despite these clues, C19orf43 still lacks functional annotation in major protein databases (e.g., UniProt). Ongoing research focuses on CRISPR-based functional screening and structural characterization to elucidate its contribution to fundamental biological processes or pathology. Its conservation across vertebrates underscores potential biological significance awaiting discovery.
×
